SLC6A9 (GlyT1) Drug Discovery Landscape & Assay Solutions
Market Intelligence, Clinical Progress, and High-Purity Reagents for CNS Disorder Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC6A9 (GlyT1) Recombinant Transporter Protein Multi-pass membrane preparation. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View SLC6A9 Products |
| Gene Delivery | SLC6A9 (GlyT1) Premade Lentivirus Particles Full-length ORF for stable cell line construction. Native glycosylation preserved. CMV promoter. |
View SLC6A9 Products |
| Research Antibody | Anti-SLC6A9 (GlyT1) Reference Antibody Sequence Verified recombinant antibody for Western Blot and immunocytochemistry validation. |
View SLC6A9 Products |
| Validator | SLC6A9 (GlyT1) siRNA Set For knockdown verification and specificity controls in uptake assays. |
View SLC6A9 Products |
| Related Target: GlyT2 | SLC6A5 (GlyT2) Protein & Lentivirus Essential paralog for selectivity screening; distinct CNS distribution. |
View SLC6A5 Products |
| Related Target: NMDA-R | GRIN1 (NR1) Recombinant Protein NMDA receptor subunit; downstream mechanistic studies for glycine potentiation. |
View GRIN1 Products |
| Related Target: DAAO | DAAO (D-amino Acid Oxidase) Recombinant Protein Complementary glycine regulation pathway; alternative target for schizophrenia. |
View DAAO Products |
"Comprehensive reagent toolkit for SLC6A9 (GlyT1) drug discovery. Select your modality below:"
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity vs GlyT2 (SLC6A5) | Human SLC6A9 and SLC6A5 ortholog proteins available with >95% purity; Lentivirus for paralog cross-reactivity panels |
| Functional Glycine Uptake Assay | SLC6A9 Lentivirus for stable HEK293 cell lines; Native conformation preserved for radiolabeled uptake studies |
| Target Engagement Verification | SLC6A9 siRNA Set for target-specific knockdown confirmation in cellular assays |
| Species Translation (Cyno/Rat) | Ortholog variants (Human/Mouse/Rat/Cyno) sequence verified for preclinical safety pharmacology |
Live SLC6A9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC6A9 (GlyT1) inhibitors has pivoted from broad schizophrenia treatment toward selective negative symptom management and cognitive enhancement. Following first-generation non-selective inhibitor setbacks, the current R&D wave targets allosteric modulators with improved selectivity profiles over the spinal cord-enriched paralog GlyT2. As second-generation small molecules advance through Phase 2 trials, the field anticipates combination therapies with NMDA receptor modulators and novel indications in pain processing disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Roche, Merck, Saniona, Bioprojet | Schizophrenia (Negative Symptoms), Cognitive Impairment | Selectivity Panel (GlyT1 vs GlyT2 Recombinant Proteins) |
| Allosteric Modulators | Second-gen biotechs, Academic labs | CNS Disorders, Neuropathic Pain | Conformational Binding Assay (Lentivirus-Expressing Cell Lines) |
| Dual Target Strategies | Emerging academic consortia | Treatment-Resistant Schizophrenia | Pathway |